MAP4K3 and lysosomal storage disease: MAP4K3 inhibition could thus prove to be a highly effective therapy for diseases where enhanced autophagy activation would be beneficial, including neurodegenerative disorders, lysosomal storage diseases, and possibly autoimmune disorders.